Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 4/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | FLT4 | P35916 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.30 |
| ▸ | TEK | Q02763 | 1/20 | 0.30 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30733378 | 1.00 | DGAT1 (0.35) | DGAT1PDE10ANPC1BRD4CREBBP | |
| SCHEMBL30461621 | 0.88 | DGAT1 (0.33) | DGAT1PDE10ANPC1 | |
| SCHEMBL21638105 | 0.88 | DGAT1 (0.33) | DGAT1PDE10ANPC1 | |
| SCHEMBL30712159 | 0.88 | DGAT1 (0.33) | DGAT1NPC1 | |
| Ammonia Solution, Strong SCHEMBL22418929 | 0.87 | DGAT1 (0.33) | DGAT1PDE10A | |
| SCHEMBL22252543 | 0.86 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL31343291 | 0.86 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL20588479 | 0.85 | DGAT1 (0.40) | DGAT1 | |
| SCHEMBL31343298 | 0.84 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL22252739 | 0.84 | DGAT1 (0.33) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023222005-A1 | AROMATIC HETEROCYCLIC COMPOUND AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海翊石医药科技有限公司 | 2023-11-23 | — | — | WO | disclosed |
| US-20230183243-A1 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | VORONOIBIO INC. (KR) | 2023-06-15 | — | — | US | disclosed |
| US-20230183243-A1 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | VORONOIBIO INC. (KR) | 2023-06-15 | — | — | US | disclosed |
| US-20220064161-A1 | PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF IN PREVENTION AND TREATMENT OF PROTEIN KINASE-RELATED DISEASE | VORONOI, INC. (KR) | 2022-03-03 | — | — | US | disclosed |
| WO-2020185044-A1 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | 주식회사 보로노이 | 2020-09-17 | — | — | WO | disclosed |
| WO-2020149715-A1 | PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF IN PREVENTION AND TREATMENT OF PROTEIN KINASE-RELATED DISEASE | 주식회사 보로노이 | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183243-A1 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | TTK, TTBK1, TTBK2 | DGAT1 1837/4885PDE10A 2452/4885NPC1 1231/4885 |
| US-20220064161-A1 | PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF IN PREVENTION AND TREATMENT OF PROTEIN KINASE-RELATED DISEASE | CLK1, CLK2, CLK3 | DGAT1 4027/4885PDE10A 2431/4885NPC1 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.